Key facts
- This page summarizes Vladimir Vexler's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2023, 21:02.
Vladimir Vexler - 31 Mar 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- CHRS
- Reported as of
- 31 Mar 2023
- Net transaction value
- -$111,342
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2023, 21:02:33 UTC
- Prior SEC filing
- 24 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vladimir Vexler filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 04 Apr 2023.
Change
- Previous filing in this sequence was filed on 24 Jan 2023.
- Current net transaction value: -$111,342.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CHRS
transaction
Common Stock
Tax liability
- Transaction value
- $111,342
- Shares
- -16,278
- Change %
- -12%
- Price
- $6.84
- Shares after
- 116,361
- Date
- 31 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Vladimir Vexler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
Footnote F2
Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan.